Live
10x Genomics BlogWilliam Blair upgrades 10X Genomics stock rating on AI drug discovery role - Investing.comBioPharma DiveBlackstone closes $6.3B fund for life sciences investingFierceBiotechBlackstone closes record $6.3B life sciences fundFierceBiotechAstellas axes early Sjögren’s trial in latest setback for autoimmune disease communityFierceBiotechJohnson & Johnson’s Impella pumps miss the mark in 2 major coronary studiesBioPharma DiveUnited rises on IPF data; Biogen scores positive lupus data and an approvalEndpoints News#ACC26: Merck touts comparator data for oral cholesterol drugEndpoints News#AAD26 roundup: Takeda, Alumis, Priovant and Incyte take the stageEndpoints NewsDrugmakers skeptical of new White House overtures on pricingEndpoints NewsSamsung Bio union workers threaten strike over pay, disclosure of employee dataEndpoints NewsPost-Hoc Live: Will MAHA vaccine policies be a political problem for Republicans?FierceBiotechViridian’s other rival to Amgen’s Tepezza scores phase 3 win, but investors need convincing
10x Genomics Blog Mar 30, 2026

William Blair upgrades 10X Genomics stock rating on AI drug discovery role - Investing.com

William Blair upgrades 10X Genomics stock rating on AI drug discovery role - Investing.com

Original
Body unavailable. Use the original source.

Directory

59 All